• Citer

Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial

par Jastorff, Archana;Gymnopoulou, Efi;Salas, Jose;Merrall, Elizabeth;Buntinx, Erik;Martin, Charlotte ;Askling, Helena Hervius;Schenkenberger, Isabelle;Yuste, Angela Cano;Smith, William;Sotolongo, Roberto;Von Engelhardt, Charlotte;Bastian, Arangassery Rosemary;Comeaux, Christy;Ligtenberg, Nynke;Callendret, Benoit;Heijnen, Esther
Référence Vaccine, 43, 126514
Publication Publié, 2025-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial
Auteur:	Jastorff, Archana; Gymnopoulou, Efi; Salas, Jose; Merrall, Elizabeth; Buntinx, Erik; Martin, Charlotte; Askling, Helena Hervius; Schenkenberger, Isabelle; Yuste, Angela Cano; Smith, William; Sotolongo, Roberto; Von Engelhardt, Charlotte; Bastian, Arangassery Rosemary; Comeaux, Christy; Ligtenberg, Nynke; Callendret, Benoit; Heijnen, Esther
Informations sur la publication:	Vaccine, 43, 126514
Statut de publication:	Publié, 2025-01
Sujet CREF:	Pathologie maladies infectieuses
	Biologie moléculaire
	Santé publique
	Sciences et médecine vétérinaires
	Immunologie
	Microbiologie et protistologie [bacteriol.,virolog.,mycolog.]
Mots-clés:	Adult
	Comorbidity
	Immunogenicity
	Respiratory syncytial virus
	Safety
	Vaccine
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0264-410X
	info:doi/10.1016/j.vaccine.2024.126514
	info:pii/S0264410X24011964
	info:scp/85208579950
	info:pmid/39536455